Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	COMPASS Pathways	Repare Therapeutics	Dynavax Technologies	Ocular Therapeutix	Kronos Bio
Symbol	NASDAQ:CMPS	NASDAQ:RPTX	NASDAQ:DVAX	NASDAQ:OCUL	NASDAQ:KRON
Price Information
Current Price	$34.39	$32.38	$7.80	$14.81	$24.80
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.5	1.6	1.7	1.6	1.7
Analysis Score	3.5	2.5	3.5	3.5	3.5
Community Score	3.8	3.9	2.5	3.0	4.2
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	0.8	1.7	0.8	0.0
Earnings & Valuation Score	0.0	0.6	0.6	0.6	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$70.80	$40.20	$16.33	$24.80	$43.67
% Upside from Price Target	105.87% upside	24.15% upside	109.40% upside	67.45% upside	76.08% upside
Trade Information
Market Cap	$1.37 billion	$1.20 billion	$893.79 million	$1.13 billion	$1.39 billion
Beta	N/A	N/A	1.34	2.29	N/A
Average Volume	430,150	140,263	5,086,389	1,082,729	180,839
Sales & Book Value
Annual Revenue	N/A	N/A	$35.22 million	$4.23 million	N/A
Price / Sales	N/A	N/A	25.38	267.11	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	N/A	N/A	$0.10 per share	($0.08) per share	N/A
Price / Book	N/A	N/A	78.00	-185.13	N/A
Profitability
Net Income	$-19,610,000.00	N/A	$-152,600,000.00	$-86,370,000.00	N/A
EPS	N/A	N/A	($1.87)	($2.01)	N/A
Trailing P/E Ratio	0.00	0.00	N/A	N/A	0.00
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	-256.92%	-780.19%	N/A
Return on Equity (ROE)	N/A	N/A	-193.85%	-14,065.71%	N/A
Return on Assets (ROA)	N/A	N/A	-23.45%	-81.81%	N/A
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	2.59%	8.86%	N/A
Current Ratio	42.12%	35.44%	4.35%	3.58%	N/A
Quick Ratio	42.11%	35.44%	3.47%	3.53%	N/A
Ownership Information
Institutional Ownership Percentage	15.78%	64.81%	80.02%	52.45%	N/A
Insider Ownership Percentage	N/A	N/A	13.33%	7.70%	N/A
Miscellaneous
Employees	61	102	245	181	63
Shares Outstanding	39.93 million	36.98 million	114.59 million	76.29 million	56.07 million
Next Earnings Date	N/A	8/12/2021 (Estimated)	8/5/2021 (Estimated)	8/6/2021 (Estimated)	8/10/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Optionable	Optionable	Not Optionable

Source	Headline
	Kronos Bio (NASDAQ:KRON) Sees Strong Trading Volume americanbankingnews.com - May 14 at 11:32 AM
	Kronos Bio (NASDAQ:KRON) Trading Up 8.7% americanbankingnews.com - May 13 at 11:38 AM
	Kronos Bio (NASDAQ:KRON) Issues Quarterly Earnings Results americanbankingnews.com - May 12 at 12:40 PM
	Kronos Bio (NASDAQ:KRON) Shares Gap Up to $24.48 americanbankingnews.com - May 12 at 10:58 AM
	Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces ... apnews.com - May 11 at 5:05 PM
	Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D Day finance.yahoo.com - May 11 at 5:05 PM
	Kronos Bio (NASDAQ:KRON) Stock Price Down 5.1% americanbankingnews.com - May 7 at 12:44 PM
	Kronos Bio Announces Participation in Bank of America Securities 2021 Health Care Conference finance.yahoo.com - May 6 at 2:29 PM
	Kronos Bio, Inc. (NASDAQ:KRON) Sees Large Increase in Short Interest americanbankingnews.com - May 4 at 4:44 PM
	Kronos Bio (NASDAQ:KRON) Sees Large Volume Increase americanbankingnews.com - May 3 at 12:04 PM
	Kronos Bio (NASDAQ:KRON) Stock Price Up 5% americanbankingnews.com - April 30 at 1:46 PM
	Kronos Bio (NASDAQ:KRON) Shares Gap Up to $23.19 americanbankingnews.com - April 27 at 10:52 AM
	Here's What Kronos Bio, Inc.'s (NASDAQ:KRON) Shareholder Ownership Structure Looks Like nasdaq.com - April 23 at 11:56 PM
	Kronos Bio (NASDAQ:KRON) Stock Price Up 9.2% americanbankingnews.com - April 22 at 11:54 AM
	Kronos Bio (NASDAQ:KRON) Sees Unusually-High Trading Volume americanbankingnews.com - April 21 at 11:40 AM
	What Type Of Shareholders Own The Most Number of Kronos Bio, Inc. (NASDAQ:KRON) Shares? finance.yahoo.com - April 11 at 1:30 PM
	Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained ... apnews.com - April 10 at 11:19 AM
	Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR Annual Meeting 2021 finance.yahoo.com - April 10 at 11:19 AM
	After 21 Years In Private Practice, GC Finds Her '2nd Chapter' law360.com - April 5 at 5:33 PM
	Kronos Bio Appoints Taiyin Yang, Ph.D., to Board of Directors finance.yahoo.com - March 26 at 12:39 PM
	Kronos Bio Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results finance.yahoo.com - March 23 at 6:13 PM
	Kronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual Meeting 2021 for KB-0742, an ... apnews.com - March 11 at 8:42 AM
	Kronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual Meeting 2021 for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers finance.yahoo.com - March 10 at 7:53 PM
	Biopharma GC Appointed To Athira Pharma's Board law360.com - March 8 at 7:38 PM
	The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company msn.com - March 4 at 9:43 AM

Date	Company	Brokerage	Action
5/11/2021	COMPASS Pathways	Cantor Fitzgerald	Initiated Coverage
4/1/2021	COMPASS Pathways	Roth Capital	Initiated Coverage
10/14/2020	COMPASS Pathways	HC Wainwright	Initiated Coverage
10/13/2020	COMPASS Pathways	Evercore ISI	Initiated Coverage
10/13/2020	COMPASS Pathways	Canaccord Genuity	Initiated Coverage
10/13/2020	COMPASS Pathways	Cowen	Initiated Coverage
10/13/2020	COMPASS Pathways	Berenberg Bank	Initiated Coverage
4/26/2021	Repare Therapeutics	Morgan Stanley	Boost Price Target
12/29/2020	Repare Therapeutics	Northland Securities	Reiterated Rating
9/17/2020	Repare Therapeutics	Bloom Burton	Reiterated Rating
7/14/2020	Repare Therapeutics	The Goldman Sachs Group	Initiated Coverage
7/14/2020	Repare Therapeutics	Piper Sandler	Initiated Coverage
12/18/2020	Dynavax Technologies	William Blair	Reiterated Rating
5/24/2019	Dynavax Technologies	Royal Bank of Canada	Lower Price Target
12/30/2020	Ocular Therapeutix	JMP Securities	Boost Price Target
11/13/2020	Ocular Therapeutix	Raymond James	Boost Price Target
3/17/2020	Ocular Therapeutix	Jefferies Financial Group	Initiated Coverage
11/12/2019	Ocular Therapeutix	Piper Jaffray Companies	Lower Price Target

(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources